Current medical research and opinion
-
Randomized Controlled Trial Multicenter Study Comparative Study
A randomized placebo-controlled trial of duloxetine in patients with major depressive disorder and associated painful physical symptoms.
Painful physical symptoms are common in patients with major depressive disorder (MDD) and may predict poorer treatment outcomes. Duloxetine has demonstrated efficacy in treating both MDD and certain other painful conditions. This randomized, double-blind clinical trial assessed the effects of duloxetine in patients with both MDD and MDD-associated physical pain. ⋯ These results support the efficacy and tolerability of duloxetine in the treatment of depression and associated painful physical symptoms in patients with MDD and at least moderate MDD-associated pain.
-
Randomized Controlled Trial Multicenter Study Comparative Study
Duloxetine versus placebo in the treatment of major depressive disorder and associated painful physical symptoms: a replication study.
Painful physical symptoms are common in patients with major depressive disorder (MDD) and can negatively affect patient outcomes. Duloxetine has demonstrated efficacy in treating MDD and other certain painful conditions; this study specifically evaluated patients with both MDD and MDD-associated pain. ⋯ These results replicated findings supporting the efficacy and tolerability of duloxetine compared to placebo as treatment for depression and pain in patients with MDD and at least moderate pain associated with MDD.
-
Chronic non-cancer pain - unlike acute pain, which can be regarded as a symptom of disease or injury - is gaining recognition as a disease in its own right. It is a burden for the individual sufferer that has a severe impact on physical and social functioning. ⋯ The CHANGE PAIN initiative aims to enhance the understanding of patients who suffer from severe chronic pain and to improve pain management. The following special supplement, consisting of 10 commentaries, describes the proceedings from the first international Expert Meeting of the CHANGE PAIN initiative, which was held in Rome on June 20th and 21st, 2010.
-
Rituximab in combination with fludarabine and cyclophosphamide has significantly improved outcomes for patients with chronic lymphocytic leukemia (CLL) and an improvement in overall survival has recently been shown for the first time in the history of CLL treatment. However, the chemotherapy portion of this regimen may be unsuitable for elderly patients or those with significant comorbidities. We investigated the safety and tolerability of single-agent rituximab in 23 consecutive patients presenting with CLL at a single institution. ⋯ Rituximab was well tolerated with no unexpected adverse events even at the highest dose. These results indicate that single-agent rituximab is effective and has a place in the treatment of CLL.